251 related articles for article (PubMed ID: 25545854)
1. Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: the role of NF-κB and PPAR-γ.
Alves ÉAR; de Miranda MG; Borges TK; Magalhães KG; Muniz-Junqueira MI
Int Immunopharmacol; 2015 Feb; 24(2):314-324. PubMed ID: 25545854
[TBL] [Abstract][Full Text] [Related]
2. HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis.
Alvarenga DLR; Silva AHDS; Fiuza JA; Gaze ST; de Oliveira JG; Oliveira RC; Calzavara-Silva CE; Pascoal-Xavier MA; Alves ÉAR
Int Immunopharmacol; 2018 Jul; 60():179-188. PubMed ID: 29747123
[TBL] [Abstract][Full Text] [Related]
3. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
4. Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.
Auclair M; Afonso P; Capel E; Caron-Debarle M; Capeau J
Antivir Ther; 2014; 19(8):773-82. PubMed ID: 24535489
[TBL] [Abstract][Full Text] [Related]
5. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
6. Effect of HIV protease inhibitors on New World Leishmania.
Demarchi IG; Silveira TG; Ferreira IC; Lonardoni MV
Parasitol Int; 2012 Dec; 61(4):538-44. PubMed ID: 22579524
[TBL] [Abstract][Full Text] [Related]
7. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
Stanley TL; Joy T; Hadigan CM; Liebau JG; Makimura H; Chen CY; Thomas BJ; Weise SB; Robbins GK; Grinspoon SK
AIDS; 2009 Jul; 23(11):1349-57. PubMed ID: 19474651
[TBL] [Abstract][Full Text] [Related]
8. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
[TBL] [Abstract][Full Text] [Related]
10. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
[TBL] [Abstract][Full Text] [Related]
11. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
Ferrer E; del Rio L; Martínez E; Curto J; Domingo P; Ribera E; Negredo E; Rosales J; Saumoy M; Ordóñez J; Gatell JM; Podzamczer D
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1061-5. PubMed ID: 21166602
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
[TBL] [Abstract][Full Text] [Related]
13. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
Noor MA; Parker RA; O'Mara E; Grasela DM; Currie A; Hodder SL; Fiedorek FT; Haas DW
AIDS; 2004 Nov; 18(16):2137-44. PubMed ID: 15577646
[TBL] [Abstract][Full Text] [Related]
14. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
Slish J; Ma Q; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau D; Boston NS; Catanzaro L; DiFrancesco R; Morse GD
Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
Perry ME; Taylor GP; Sabin CA; Conway K; Flanagan S; Dwyer E; Stevenson J; Mulka L; McKendry A; Williams E; Barbour A; Dermont S; Roedling S; Shah R; Anderson J; Rodgers M; Wood C; Sarner L; Hay P; Hawkins D; deRuiter A
HIV Med; 2016 Jan; 17(1):28-35. PubMed ID: 26200570
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
[TBL] [Abstract][Full Text] [Related]
17. Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.
Rathbun CR; Liedtke MD; Blevins SM; Harrison D; Lockhart SM; Salvaggio M; Acosta EP
HIV Clin Trials; 2009; 10(5):328-36. PubMed ID: 19906626
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Malan N; Su J; Mancini M; Yang R; Wirtz V; Absalon J; McGrath D;
AIDS Care; 2010 Jun; 22(6):677-86. PubMed ID: 20467943
[TBL] [Abstract][Full Text] [Related]
19. Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations.
Alhalaweh A; Bergström CAS; Taylor LS
J Control Release; 2016 May; 229():172-182. PubMed ID: 27006280
[TBL] [Abstract][Full Text] [Related]
20. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
